Approved and investigational biologics typically are delivered via intravenous administration that can require expensive, inconvenient and routine hospital or clinic visits. Enable Injections LLC expects that it has a solution with its subcutaneous drug delivery wearable – and the multiple pharma partners it has lined up, including Paris-based Sanofi SA, apparently agree.
FDA has approved the Valiant Navion thoracic stent graft system for the minimally invasive repair of descending thoracic aorta lesions from Medtronic plc. The system from the Dublin-based company is a new iteration of the prior Valiant Captivia thoracic stent graft system, which has been used on more than 100,000 patients globally.
The latest med-tech IPO comes from SI-Bone Inc., which managed to price at the high end of its proposed range and upsized the offering. That's despite a turbulent broader market and a slew of other life sciences offerings; these trends could make it difficult to get med-tech IPOs done if they continue. But, med-tech IPOs have been getting bigger and splashier; this is at least the sixth IPO to raise over $100 million in 2018. (See BioWorld MedTech, Oct. 8, 2018.)
Wyss Institute researchers have shown that gold nanoparticles can help extend the half-life of investigational cytokine interleukin 4 (IL-4), which is known to boost anti-inflammatory activity but degrades too quickly when injected alone to produce the desired effect.
Cardialen Inc. aims to alter the field of cardiac defibrillation therapy by offering an implant that offers a low-energy shock that could reduce associated mortality issues, as well as eliminate the pain and discomfort that occurs. It is in the middle of a pivotal study of an external device to test its approach and then it plans to develop an implant.
Cambridge, Mass.-based Glympse Bio Inc. has raised $22 million in a series A financing that's intended to get the company into the clinic in its first couple of indications, as well as to advance it into pharma partnerships. The startup is pursuing a novel approach to diagnostics, as well as treatment and recurrence monitoring, that relies upon an injectable sensor that is activated by disease processes and then becomes detectable in patient urine within about an hour.
Wyss Institute researchers have shown that gold nanoparticles can help extend the half-life of investigational cytokine interleukin 4 (IL-4), which is known to boost anti-inflammatory activity but degrades too quickly when injected alone to produce the desired effect.
